Overview

Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL

Status:
Withdrawn
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
To determine the efficacy of MAT9001 compared to placebo in lowering fasting triglyceride levels in subjects with very high fasting triglyceride levels ≥ 500 and < 2000 mg/dL.
Phase:
Phase 3
Details
Lead Sponsor:
Matinas Biopharma, Inc
Collaborator:
Covance